01 — At a Glance
The Specialty Chemicals Grind (But Make It Profitable)
- 52-Week High / Low₹852 / ₹535
- CMP (13 Mar 2026)₹558
- Q3 FY26 Revenue₹1,051 Cr
- Q3 FY26 PAT₹47 Cr (ex-exceptional)
- Q3 FY26 EPS₹2.94
- Book Value₹191
- Price to Book2.92x
- Dividend Yield0.90%
- Debt / Equity0.27x
- Interest Coverage8.28x
Opening Auditor Note: Jubilant Ingrevia reported ₹1,051 crore revenue in Q3 FY26 (flat YoY). EBITDA margins at 12.9% (up 60 bps QoQ despite broad-based pricing pressure). 9M FY26 PAT growth stands at +33.2% YoY. The stock is down 19.8% over 3 months and trading at a P/E of 32.3x — which is spicy for a chemicals company dealing with volatile commodity pricing and a major CDMO ramp coming. But specialty segments? Margins are above 25%. Agro CDMO? First shipments in March. The market seems to have priced in everything except the upside.
02 — Introduction
Welcome to the Specialty Chemicals Theatre: Where Boring = Bankable
Jubilant Ingrevia is not a startup. It’s not disrupting anything. It doesn’t have a secret algorithm. What it does have is 40+ years of quietly building a global business in three things: fancy chemicals (pyridines, diketenes, fine chemicals), vitamin B3 and related nutrition products, and chemical intermediates (acetyls — think paracetamol precursors).
The company serves 15 of the world’s top 20 pharma firms and 7 of the top 10 agrochemical companies. Global presence: USA, EU, Japan, China, Singapore. Manufacturing footprint: 5 plants across India. Revenue breakdown: 43% specialty chemicals, 39% chemical intermediates, 18% nutrition — though the company is deliberately shifting mix toward the higher-margin, less-volatile specialty and nutrition segments.
Q3 FY26 was textbook specialty chemicals: pricing got hammered across the board, but volume growth hit double digits. Management called the pricing cycle as “bottomed out.” CDMO (contract development and manufacturing) opportunity funnel now exceeds 100 active opportunities worth ₹3,500 crore in peak annual revenue potential. The major agro CDMO order — the one everyone’s been waiting for — is finally shipping next month. Stock is down 19.8% in three months. Apparently, the market hates clarity.
Q3 Concall Highlight (Feb 2026): CEO: “Pricing has bottomed out… we have not seen any significant further decline in price over the last six months.” Also CEO: “We have seen almost 7-8% increase in price of Vitamin B3 feed grade in the last few days.” Translation: The grind is ending. The recovery is starting. Welcome to the setup.
03 — Business Model: Chemicals, But Make It Global
They Make Stuff That Goes Into Other Stuff That You Buy
Jubilant manufactures over 134 products sold to 1,500+ customers. Three segments. Three business models.
Segment 1: Specialty Chemicals (43% of revenue) — Pyridines, picolines, diketenes, fine chemicals for pharma and agrochemical manufacturers. Jubilant is the largest non-China-based manufacturer globally in 36 pyridine derivatives. They control vertical integration — pyridine is made in-house, converted to higher-value derivatives, sold to OEMs. Margins above 25% even under pricing stress. CDMO is the growth play here: design a drug molecule manufacturing process for a pharma firm, build the facility to their specs, run it exclusively. Minimum margins: 20% EBITDA, 20% ROCE.
Segment 2: Chemical Intermediates (40% of revenue) — Acetic acid derivatives: ethyl acetate, acetic anhydride. The paracetamol precursor. Commodity-like margins, high leverage to input costs and end-product pricing. Q3 was weak: acetic acid prices fell, realisations compressed. But acetic acid just bounced, which means anhydride and ethyl acetate should follow. This segment is the cash cow but also the margin volatility culprit.
Segment 3: Nutrition & Health (18% of revenue) — Vitamin B3 (niacinamide), choline, premixes for animal and human nutrition. Rank #2 globally in B3. Growing double digits. Just got a 7-8% price bump in the last month. Margins recovering as mix shifts from feed-grade (lower margin) to food and cosmetics grades (higher margin).
The Risk Nobody’s Discussing: 47% of FY25 revenue came from exports. Currency fluctuations matter. FX hedging helps, but base oil is dollar-linked. INR weakness = margin compression. That said, natural hedge exists because 50% of costs are also linked to international commodity prices.
💬 Which segment excites you most: the CDMO ramp, the vitamin B3 recovery, or the agro intermediate turnaround? Drop a comment!
04 — Financials Overview
Q3 FY26: The Numbers That Matter
Continue reading with a premium membership.
